Autologous tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.
Amanda Guth
Advertisement
Amanda Guth, DVM, PhD, is the chief scientific officer for PhotonPharma.
Articles by Amanda Guth
Advertisement
Latest Updated Articles
Advertisement
Advertisement